Chirwere chegomarara chemapapu ndicho chimwe chezvikonzero zvinokonzeresa kufa kwevanhu nekuda kwemamota, uye huwandu hwayo hwekufa uye huwandu hwekufa hwakaiswa pekutanga mumaguta. Iyo pathology inonyanya kusiri diki-diki kenza yemapapu (NSCLC), inoverengera 85%. Varwere vazhinji vanenge vari pakati nepakati nepakati pezvinhanho pavanoonekwa, uye 60 kusvika 80% yevarwere vekenza yemapapu vakarasikirwa nemukana wekuvhiyiwa kana vanyatsoonekwa. Panguva imwecheteyo, mapapu inhengo yechipiri zviri nyore metastatic yemamota akasimba, ichiteverwa nematastases echiropa. Kuvhiya kurapwa kunowanzoshandiswa kune varwere vane mashoma uye mashoma nhamba yemametastases. Kuvhiya kunoda kubviswa kwechikamu chetishu yemapapu ine basa remazuva ose. Nokudaro, nzira itsva dzokurapa dzinodiwawo kutsiva kuvhiyiwa.
In recent years, the minimally invasive radiofrequency ablation (RFA) technology has been used more and more as a minimally invasive treatment method in the treatment of primary / secondary lung tumors, and has made great progress, known as the treatment “Dinghaishen Needle” for kenza yemapapu.
Chii chinonzi radio frequency ablation?
Radiofrequency ablation consists of an electrode needle inserted into the tumarara tissue and an electrode plate attached to the patient’s body to form a current loop. After the RF generator is turned on, high-frequency alternating current at the electrode tip is injected into the target tissue (Figure 2A), causing ions in the tissue to occur Shock, friction and heat generation will follow, causing cell death and coagulation necrosis in the target tissue around the electrode (Figure 2B). At the same time, the vascular tissue around the tumor will coagulate to form a reaction zone, preventing it from continuing to supply blood to the tumor and preventing tumor metastasis. Radio frequency waves can also cause tumor blood vessels to coagulate and reduce blood supply. At the same time, the ablated tumor tissue remains in the body. Due to its composition and structural changes, it can stimulate the body’s immunity and produce anti-tumor cytotoxic antibodies, and induce cytotoxic T cell immunity.
Ndeapi magomarara emapapu anoshandiswa neRFA?
1. Used for isina-diki kenza yemapapu kenza that cannot tolerate surgery. Tumor diameter ≤2cm, 78 ~ 96% of patients can achieve complete ablation; tumor diameter ≤3cm, 5-year survival rate exceeds 50%. The treatment effect is better for primary lung cancer with a diameter ≤5cm.
2. For the treatment of lung metastases. Studies have shown that lung metastases with a diameter ≤2-3 cm, patients with lung metastases receiving RFA treatment have a 3-year survival rate of 53.7% and a 4-year survival rate of 44.1%. As shown in Figure 3, a kenza yebonde patient relapsed with a single left lung metastasis. After RFA treatment, the follow-up and follow-up for nearly 3 years showed a good quality of life and no distant recurrence.
3. Murwere, mukadzi, ane makore makumi mana nemasere, ane metastasis yemapapu imwe chete mushure mekuvhiyiwa kenza yemazamu. Kurapa kwevarwere vane kenza yemapapu isiri-diki yemapapu, kusanganisira tyrosine kinase inhibitors (TKI), yakadai seKemena, Iressa kana Trocaine mushure mekudzivirira zvinodhaka. Semuyenzaniso, kurapwa kweTKI kwave nzira yekutanga yekurapa kune varwere vane advanced epidermal growth factor receptor (EGFR) inonzwisisika shanduko mune yepamusoro isiri-diki cell cancer yemapapu. Shao Yifu Chipatara cheCancer Research Center chinoshandisa tekinoroji yeRFA yekurapa kusinga diki kenza yemapapu uye imwe yedzimwe nzira dzekurapa kukunda TKI kuramba.
4: Mukadzi ane makore makumi mashanu nemapfumbamwe ane kenza yemapapu isiri-diki (EGFR mutation) ine intra-pulmonary metastasis, mwedzi 59 mushure mekurapwa kwemuromo TKI, bundu repazasi rekurudyi (Mufananidzo B) rinonyanya kuoneka kupfuura rakapfuura. (Mufananidzo A) sezvinoratidzwa nemuseve Kuwedzera, kufambira mberi kwechirwere; CT-inotungamirirwa RFA kurapwa kwezasi kwerudyi bundu remapapu (Mufananidzo C), yakateverwa kwemwedzi ye15 (Mufananidzo D), mwedzi mitanhatu (Mufananidzo E) yakaratidza kutonga kwakanaka.
4. Yakasanganiswa nechemotherapy uye radiotherapy. Chemotherapy uye radiotherapy yakasanganiswa neradiofrequency ablation therapy inoshandiswa pakuita metastatic chiropa nemapapu. Iko kusanganiswa kwekushandisa kwevaviri kunogona kugadzirisa kusakwana kwavo uye kuwedzera kushanda. Kuenzaniswa nechero nzira imwe chete yekurapa, inorebesa nguva yekurarama kwemurwere uye inovandudza hupenyu.
The patient, a 58-year-old male, has colon cancer with multiple liver and lung metastases in the distance, making it difficult to operate and treat. Combined with chemotherapy and targeted drug therapy, especially combined with minimally invasive radiofrequency ablation technology, it successfully cured liver and lung metastases.
5. RFA can also be used for palliative treatment to relieve various discomfort symptoms of patients with advanced lung cancer.
6: Murwere wekenza yemapapu ane makore makumi masere nemasere akadzoka zvakare ne intra-pulmonary uye pleural metastasis (inoratidzwa muFigure A uye B). Kurwadziwa kwakanyanya kunonetsa kurara. Kurwadziwa kwemurwere kwakadzikiswa zvakanyanya mushure mekurapwa kweRFA yemamota emapapu, uye kunaka kwekurara kwakavandudzwa zvakanyanya. Mushure megore rekutevera, murwere aigara ari muchimiro chakanaka nemamota emapapu akatsiga.
